Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Share-based Compensation (2020 - 2025)

Historic Share-based Compensation for Foghorn Therapeutics (FHTX) over the last 6 years, with Q3 2025 value amounting to $2.7 million.

  • Foghorn Therapeutics' Share-based Compensation fell 944.33% to $2.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.6 million, marking a year-over-year decrease of 1460.56%. This contributed to the annual value of $11.9 million for FY2024, which is 2652.29% down from last year.
  • According to the latest figures from Q3 2025, Foghorn Therapeutics' Share-based Compensation is $2.7 million, which was down 944.33% from $2.7 million recorded in Q2 2025.
  • Foghorn Therapeutics' Share-based Compensation's 5-year high stood at $4.6 million during Q1 2023, with a 5-year trough of $1.9 million in Q1 2021.
  • In the last 5 years, Foghorn Therapeutics' Share-based Compensation had a median value of $3.1 million in 2023 and averaged $3.1 million.
  • As far as peak fluctuations go, Foghorn Therapeutics' Share-based Compensation soared by 31758.69% in 2021, and later crashed by 2948.38% in 2024.
  • Foghorn Therapeutics' Share-based Compensation (Quarter) stood at $2.1 million in 2021, then soared by 81.43% to $3.8 million in 2022, then dropped by 19.31% to $3.1 million in 2023, then dropped by 18.62% to $2.5 million in 2024, then grew by 10.07% to $2.7 million in 2025.
  • Its Share-based Compensation was $2.7 million in Q3 2025, compared to $2.7 million in Q2 2025 and $2.7 million in Q1 2025.